Estrogen regulates the amount of white adipose tissue (WAT) in females, but its role in males and whether WAT effects involve estrogen receptor-␣ (ER␣) or ER␤ were unclear. We analyzed the role of ER␣ in WAT and brown adipose tissue by comparing these tissues in wild-type (WT) and ER␣-knockout (␣ERKO) male and female mice. Brown adipose tissue weight was similar in ␣ERKO and WT males at all ages. Progressive increases in WAT were seen in ␣ERKO males with advancing age. Epididymal, perirenal, and inguinal WAT weighed 139 -185% more in ␣ERKO than in WT males by 270 -360 days of age. Epididymal and perirenal adipocyte size was increased 20% in ␣ERKO males. Adipocyte number was 82-168% greater in fat pads of ␣ERKO vs. WT males. Compared with WT, 90-day-old ␣ERKO females had increases in fat pad weights (54 -103%), adipocyte size, and number. Both ␣ERKO males and females had insulin resistance and impaired glucose tolerance, similar to humans lacking ER␣ or aromatase. Energy intake was equal in WT and ␣ERKO males, indicating that obesity was not induced by hyperphagia. In contrast, energy expenditure was reduced by 11% in ␣ERKO compared with WT males, indicating that altered energy expenditure may be important for the observed obesity. In summary, ER␣ absence causes adipocyte hyperplasia and hypertrophy, insulin resistance, and glucose intolerance in both sexes. These results are evidence that estrogen͞ER␣ signaling is critical in female and male WAT; obesity in ␣ERKO males involves a mechanism of reduced energy expenditure rather than increased energy intake. O besity is a significant human health problem whose incidence is reaching epidemic proportions in some Western countries. For example, obesity in Americans has risen dramatically in the past 40 years, from 12.8% in 1962 to 22.5% in 1998, and 55% of the population is considered overweight (1). Obesity is associated with increased type II diabetes, heart disease, certain cancers, and other health problems, and obesity is estimated to be responsible for 300,000 deaths͞year in the U.S. (2). Because of these human health concerns, there is intense interest in factors that regulate development and function of white adipose tissue (WAT). In addition, factors regulating WAT in food animals are important because of concerns over excess fat consumption in Western diets, which may contribute to adverse health effects.Evidence from both humans and laboratory animals suggests that estrogen plays an important role in WAT regulation. Ovariectomy of rodents increases WAT, and estrogen replacement decreases WAT (3). Similarly, postmenopausal women have increased WAT, and estrogen therapy decreases WAT levels compared with untreated postmenopausal women (4).Female WAT expresses the classical estrogen receptor, estrogen receptor-␣ (ER␣), as well as the recently described ER␤ (5-8). Although the relative role of ER␣ and ER␤ and the mechanism by which estrogen regulates WAT are unclear, estrogen effects on glucose homeostasis in females may be involved (9). For example, glucose to...

Oestrogen is considered to be the 'female' hormone, whereas testosterone is considered the 'male' hormone. However, both hormones are present in both sexes. Thus sexual distinctions are not qualitative differences, but rather result from quantitative divergence in hormone concentrations and differential expressions of steroid hormone receptors. In males, oestrogen is present in low concentrations in blood, but can be extraordinarily high in semen, and as high as 250 pg ml −1 in rete testis fluids 1,2 , which is higher than serum oestradiol in the female 3 . It is well known that male reproductive tissues express oestrogen receptors [4][5][6][7] , but the role of oestrogen in male reproduction has remained unclear. Here we provide evidence of a physiological role for oestrogen in male reproductive organs. We show that oestrogen regulates the reabsorption of luminal fluid in the head of the epididymis. Disruption of this essential function causes sperm to enter the epididymis diluted, rather than concentrated, resulting in infertility. This finding raises further concern over the potential direct effects of environmental oestrogens on male reproduction and reported declines in human sperm counts 8,9 .Classic cellular responses to the hormone oestrogen are mediated through nuclear oestrogen receptors (ER), which function as ligand-dependent transcription factors. Efferent ductules of the testis are known to express high amounts of ER-α 10,11 , higher even than uterine tissue, and both the α and β forms of ER are present in efferent ductules and the epididymis 10 . These ductules form a series of small tubules that transport sperm from the testis to the epididymis 12 . In humans, one third of the epididymal head consists of efferent ductules 13 . In addition to ciliated cells that stir the luminal fluid, their epithelia contain nonciliated cells that resemble proximal tubule cells in the kidney. The non-ciliated cells have a reabsorptive function that results in the uptake of water, ions and proteins from the ductal lumen 12,14 . Ductules in the rat reabsorb nearly 90% of the rete testis fluid, coupling water and active ion transport in an electroneutral environment, in which Na + and water are reabsorbed at equal rates, thereby increasing the concentration of sperm as they enter the Correspondence and requests for materials should be addressed to R.A.H. (r-hess@uiuc.edu). 15,16 . This method of concentrating sperm improves their survival and maturation during epididymal storage and ensures that a large number of sperm are released upon ejaculation, increasing the randomness of fertilization and providing genetic variation 14 . These data and the observation that efferent ductules contain the highest concentrations of ER in the male led us to hypothesize that oestrogen participates in the regulation of fluid reabsorption in the male reproductive tract. HHS Public AccessTo test this hypothesis, we used the ER-α gene knockout mouse (ERKO) 17,18 . The ERKO male is infertile 18 , but its testes appear normal un...

During the past decade a number of pesticides, industrial by-products, manufactured products such as plastics, and natural chemicals have been shown to disrupt the endocrine system. These chemicals are referred to as endocrine-disrupting chemicals (EDCs). These chemicals have received considerable attention, in part because endocrine disruption is a relatively unstudied area in toxicology and is only recently being taken into account in risk assessment. The focus here is on EDCs with estrogenic activity (EEDCs), which are chemicals that act as hormone mimics via estrogen receptor mechanisms; this is currently the largest group of known endocrine disruptors. The main purpose of this article is to present an overview of the mechanisms of hormone action that provide the basis for understanding how EEDCs have the potential to be biologically active at low, environmentally relevant doses. Our strategy is to discuss the receptor mechanisms mediating responses to a natural hormone, 17β-estradiol (E 2 ), and then to use this information as the basis for describing the low-dose effects of chemicals that disrupt the normal functioning of this hormonal system, either by mimicking, modulating, or antagonizing the activity of the hormone. We have chosen to use estrogen as our example because there is more known about the biology of estrogens and xenoestrogens than other components of the endocrine system for which there is evidence for disruption by environmental chemicals; however, the information presented here is applicable to endocrine disruptors that interfere with other hormonal systems.We will begin by briefly reviewing information concerning the relationship between dose, receptor occupancy, and responses (such as cell proliferation) after binding of E 2 to estrogen receptors (ER-α) in cultured human MCF-7 breast cancer cells. A number of specific factors influence the dose of an EEDC that reaches the target cells to produce a response. These factors include route of administration, absorption, distribution, metabolism, rate of clearance, plasma transport, cell uptake, affinity for estrogen receptor subtype in the cell, and the interaction of the ligand-receptor complex with tissue-specific factors comprising the transcriptional apparatus. This mechanistic information provides the basis for establishing the dose at the target site in cells (nuclear receptors associated with DNA or more recently identified receptors associated with the cell membrane) for an EEDC required to elicit a biological response similar to that produced by a dose of E 2 with equal estrogenic activity. Modeling that takes into account each of these factors would encompass physiologically based pharmacokinetic information (1), as well as quantitative structure-activity relationships (QSAR) (2,3). We have previously discussed the factors that influence access of E 2 and EEDCs from blood to estrogen receptors in cells elsewhere (4-6). Our primary focus in this review is on the latter part of the overall process that occurs once an estrogenic chemic...

Components used in plastics, such as phthalates, bisphenol A (BPA), polybrominated diphenyl ethers (PBDE) and tetrabromobisphenol A (TBBPA), are detected in humans. In addition to their utility in plastics, an inadvertent characteristic of these chemicals is the ability to alter the endocrine system. Phthalates function as anti-androgens while the main action attributed to BPA is oestrogen-like activity. PBDE and TBBPA have been shown to disrupt thyroid hormone homeostasis while PBDEs also exhibit anti-androgen action. Experimental investigations in animals indicate a wide variety of effects associated with exposure to these compounds, causing concern regarding potential risk to human health. For example, the spectrum of effects following perinatal exposure of male rats to phthalates has remarkable similarities to the testicular dysgenesis syndrome in humans. Concentrations of BPA in the foetal mouse within the range of unconjugated BPA levels observed in human foetal blood have produced effects in animal experiments. Finally, thyroid hormones are essential for normal neurological development and reproductive function. Human body burdens of these chemicals are detected with high prevalence, and concentrations in young children, a group particularly sensitive to exogenous insults, are typically higher, indicating the need to decrease exposure to these compounds.

ObjectiveDaily adult human exposure to bisphenol A (BPA) has been estimated at < 1 μg/kg, with virtually complete first-pass conjugation in the liver in primates but not in mice. We measured unconjugated and conjugated BPA levels in serum from adult female rhesus monkeys and adult female mice after oral administration of BPA and compared findings in mice and monkeys with prior published data in women.MethodsEleven adult female rhesus macaques were fed 400 μg/kg deuterated BPA (dBPA) daily for 7 days. Levels of serum dBPA were analyzed by isotope-dilution liquid chromatography–mass spectrometry (0.2 ng/mL limit of quantitation) over 24 hr on day 1 and on day 7. The same dose of BPA was fed to adult female CD-1 mice; other female mice were administered 3H-BPA at doses ranging from 2 to 100,000 μg/kg.ResultsIn monkeys, the maximum unconjugated serum dBPA concentration of 4 ng/mL was reached 1 hr after feeding and declined to low levels by 24 hr, with no significant bioaccumulation after seven daily doses. Mice and monkeys cleared unconjugated serum BPA at virtually identical rates. We observed a linear (proportional) relationship between administered dose and serum BPA in mice.ConclusionsBPA pharmacokinetics in women, female monkeys, and mice is very similar. By comparison with approximately 2 ng/mL unconjugated serum BPA reported in multiple human studies, the average 24-hr unconjugated serum BPA concentration of 0.5 ng/mL in both monkeys and mice after a 400 μg/kg oral dose suggests that total daily human exposure is via multiple routes and is much higher than previously assumed.

Bisphenol A (BPA) is a plasticizer and an endocrine-disrupting chemical. It is present in a variety of products used daily including food containers, paper, and dental sealants and is now widely detected in human urine and blood. Exposure to BPA during development may affect brain organization and behavior, perhaps as a consequence of its actions as a steroid hormone agonist/antagonist and/or an epigenetic modifier. Here we show that BPA produces transgenerational alterations in genes and behavior. Female mice received phytoestrogen-free chow with or without BPA before mating and throughout gestation. Plasma levels of BPA in supplemented dams were in a range similar to those measured in humans. Juveniles in the first generation exposed to BPA in utero displayed fewer social interactions as compared with control mice, whereas in later generations (F(2) and F(4)), the effect of BPA was to increase these social interactions. Brains from embryos (embryonic d 18.5) exposed to BPA had lower gene transcript levels for several estrogen receptors, oxytocin, and vasopressin as compared with controls; decreased vasopressin mRNA persisted into the F(4) generation, at which time oxytocin was also reduced but only in males. Thus, exposure to a low dose of BPA, only during gestation, has immediate and long-lasting, transgenerational effects on mRNA in brain and social behaviors. Heritable effects of an endocrine-disrupting chemical have implications for complex neurological diseases and highlight the importance of considering gene-environment interactions in the etiology of complex disease.

There is increasing experimental and epidemiological evidence that fetal programming of genetic systems is a contributing factor in the recent increase in adult obesity and other components of metabolic syndrome. In particular, there is evidence that epigenetic changes associated with the use of manmade chemicals may interact with other factors that influence fetal and postnatal growth in contributing to the current obesity epidemic. The focus of this review is on the developmental effects of estrogenic endocrine disrupting chemicals (EDCs), and more specifically on effects of exposure to the estrogenic EDC bisphenol A (BPA), on adipocytes and their function, and the ultimate impact on adult obesity; BPA exposure also results in impaired reproductive capacity. We discuss the interaction of EDCs with other factors that impact growth during fetal and neonatal life, such as placental blood flow and nutrient transport to fetuses, and how these influence fetal growth and abnormalities in homeostatic control systems required to maintain normal body weight throughout life.

BackgroundIn their safety evaluations of bisphenol A (BPA), the U.S. Food and Drug Administration (FDA) and a counterpart in Europe, the European Food Safety Authority (EFSA), have given special prominence to two industry-funded studies that adhered to standards defined by Good Laboratory Practices (GLP). These same agencies have given much less weight in risk assessments to a large number of independently replicated non-GLP studies conducted with government funding by the leading experts in various fields of science from around the world.ObjectivesWe reviewed differences between industry-funded GLP studies of BPA conducted by commercial laboratories for regulatory purposes and non-GLP studies conducted in academic and government laboratories to identify hazards and molecular mechanisms mediating adverse effects. We examined the methods and results in the GLP studies that were pivotal in the draft decision of the U.S. FDA declaring BPA safe in relation to findings from studies that were competitive for U.S. National Institutes of Health (NIH) funding, peer-reviewed for publication in leading journals, subject to independent replication, but rejected by the U.S. FDA for regulatory purposes.DiscussionAlthough the U.S. FDA and EFSA have deemed two industry-funded GLP studies of BPA to be superior to hundreds of studies funded by the U.S. NIH and NIH counterparts in other countries, the GLP studies on which the agencies based their decisions have serious conceptual and methodologic flaws. In addition, the U.S. FDA and EFSA have mistakenly assumed that GLP yields valid and reliable scientific findings (i.e., “good science”). Their rationale for favoring GLP studies over hundreds of publically funded studies ignores the central factor in determining the reliability and validity of scientific findings, namely, independent replication, and use of the most appropriate and sensitive state-of-the-art assays, neither of which is an expectation of industry-funded GLP research.ConclusionsPublic health decisions should be based on studies using appropriate protocols with appropriate controls and the most sensitive assays, not GLP. Relevant NIH-funded research using state-of-the-art techniques should play a prominent role in safety evaluations of chemicals.